



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Fosphenytoin (sodium salt)

Item No. 23889

CAS Registry No.: 92134-98-0
Formal Name: 5,5-diphenyl-3-[(phosphonoxy)methyl]-2,4-imidazolidinedione, disodium salt
Synonyms: ACC-9653, CI-982
MF: C₁₆H₁₃N₂O₆P • 2Na
FW: 406.2
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fosphenytoin (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the fosphenytoin (sodium salt) in the solvent of choice. Fosphenytoin (sodium salt) is soluble in the organic solvents ethanol and DMSO, which should be purged with an inert gas. The solubility of fosphenytoin (sodium salt) in these solvents is approximately 1 mg/ml.

Description

Fosphenytoin is a prodrug of phenytoin that is rapidly converted to phenytoin, a voltage-gated sodium channel blocker, *in vivo*.¹⁻³ It induces less tissue damage compared with two other phenytoin prodrugs in rats following subcutaneous and intramuscular administration.¹ Fosphenytoin has anticonvulsant activity in a mouse model of maximal electroshock seizures similar to that of phenytoin (ED₅₀s = 16 and 8 mg/kg, respectively).² It also has antiarrhythmic activity in isolated guinea pig atria and in anesthetized dogs. Formulations containing fosphenytoin have been used in the treatment of status epilepticus.

References

1. Varia, S.A. and Stella, V.J. Phenytoin prodrugs VI: *In vivo* evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. *J. Pharm. Sci.* **73(8)**, 1087-1090 (1984).
2. Smith, R.D., Brown, B.S., Maher, R.W., *et al.* Pharmacology of ACC-9653 (phenytoin prodrug). *Epilepsia* **30(Suppl. 2)**, S15-S21 (1989).
3. Boucher, B.A. Fosphenytoin: A novel phenytoin prodrug. *Pharmacotherapy* **16(5)**, 777-791 (1996).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/18/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM